Copyright
©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 21, 2016; 22(3): 1279-1288
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1279
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1279
Emerging role of Hippo pathway in gastric and other gastrointestinal cancers
Wei Kang, Ka Fai To, Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China, Li Ka Shing Institute of Health Science, Sir Y.K. Pao Cancer Center, Institute of Digestive Disease, Partner State Key Laboratory of Digestive Disease, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
Alfred SL Cheng, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, China
Jun Yu, Department of Medicine and Therapeutics, Institute of Digestive Disease, Partner State Key Laboratory of Digestive Disease, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
Author contributions: To KF provided direction and guidance throughout the preparation of this manuscript; Kang W conducted the literature review and drafted the manuscript; Cheng ASL and Yu J reviewed the manuscript and made significant revisions on the drafts.
Supported by General Research Fund (No. 2140855, RGC Reference No. CUHK14114414) from The Research Grants Council of Hong Kong, National Natural Science Grant No. 81201591 from China, and Direct Grant for Research No. 2014.2.002 from The Chinese University of Hong Kong.
Conflict-of-interest statement: The authors report no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ka Fai To, Professor, Department of Anatomical and Cellular Pathology, State Key Laboratory in Oncology in South China, Li Ka Shing Institute of Health Science, Sir Y.K. Pao Cancer Center, Institute of Digestive Disease, Partner State Key Laboratory of Digestive Disease, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China. kfto@cuhk.edu.hk
Telephone: +852-26323334 Fax: +852-26376274
Received: April 28, 2015
Peer-review started: May 5, 2015
First decision: June 23, 2015
Revised: July 15, 2015
Accepted: November 13, 2015
Article in press: November 13, 2015
Published online: January 21, 2016
Peer-review started: May 5, 2015
First decision: June 23, 2015
Revised: July 15, 2015
Accepted: November 13, 2015
Article in press: November 13, 2015
Published online: January 21, 2016
Core Tip
Core tip: Hippo signaling pathway is a gradually emerging pathway that plays a necessary role in homeostasis of gastrointestinal tissues, whereas its deregulation frequently induces the occurrence of cancers. In gastric and other gastrointestinal cancers, the upstream components of Hippo pathway often show decreased expression and their downregulation loses the inhibitory effect on yes-associated protein 1 (YAP1)/TAZ. Thus YAP1/TAZ is translocated into the nucleus and exerts oncogenic function by direct binding with TEAD transcription factors to activate the downstream targets transcriptionally. In this brief review, we summarize the deregulation of Hippo pathway in gastric and other gastrointestinal cancers.